抗联素-23治疗与更好的困难性 Clostridioides 感染生存率有关
Gregory R Madden1,2, Robert Preissner3, Saskia Preissner3
1Division of Infectious Diseases & International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Gut microbes
|March 21, 2025
概括
抗联素-23 (IL-23) 治疗对治疗Clostridioides difficile感染有很大的希望. 与未接受抗IL-23治疗的患者相比,接受抗IL-23治疗的患者的死亡率明显较低.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 胃肠病学 胃肠病学
背景情况:
- 困难菌感染 (CDI) 是与医疗相关的感染的主要原因,尽管抗生素治疗,死亡率很高.
- 主体导向免疫疗法,特别是针对IL-23通路,是缓解CDI病原性免疫反应的潜在策略.
- 抗IL-23单克隆抗体是牛皮和炎症性肠病的已知治疗方法,涉及与CDI相关的类似Th17免疫通路.
研究的目的:
- 调查抗IL-23治疗改善了CDI住院患者的存活率的假设.
- 评估抗IL-23疗法与CDI患者30天全因死亡率之间的关联.
主要方法:
- 一个大型电子健康记录数据库的回顾性分析.
- 对抗IL-23治疗的9,301名患者和与倾向匹配的对照患者之间的生存结果的比较.
- 在住院后30天内评估所有原因的死亡率.
主要成果:
- 与对照患者 (3.1%) 相比,接受抗IL-23治疗的患者在30天内因任何原因死亡的概率显著降低 (0.54%).
- 倾向性得分匹配确保了治疗组和对照组之间的可靠比较.
结论:
- 抑制IL-23显示出作为CDI的辅助疗法的潜力.
- 需要进一步的临床试验来重新定位抗IL-23单克隆抗体用于CDI治疗,以其在其他炎症疾病中的成功为基础.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
01:27Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114